{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:05:58Z","timestamp":1784617558145,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cyto.2026.157179","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:47:36Z","timestamp":1781264856000},"page":"157179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and safety of IgG-pathway inhibitors in adult immune thrombocytopenia: A systematic review and meta-analysis with subgroup analyses of FcRn and SYK inhibitors"],"prefix":"10.1016","volume":"205","author":[{"given":"Mousa","family":"Almasalma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Hamdy","family":"Kandil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Hashem","family":"Al-Qadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Lotfy","family":"Maarouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Mohammad","family":"Altaamreh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weaam A.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed S.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Boshta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nereen A.","family":"Almosilhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashar Zahir","family":"Alsalhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mawadda","family":"Chukr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.cyto.2026.157179_bb0005","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMra010501","article-title":"Immune thrombocytopenic Purpura","volume":"346","author":"Cines","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.cyto.2026.157179_bb0010","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.cyto.2026.157179_bb0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/bjh.12480","article-title":"Cellular immune dysfunction in immune thrombocytopenia (<scp>ITP<\/scp>)","volume":"163","author":"McKenzie","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.cyto.2026.157179_bb0020","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.immuni.2017.07.009","article-title":"Fc\u03b3 receptor function and the design of vaccination strategies","volume":"47","author":"Bournazos","year":"2017","journal-title":"Immunity"},{"issue":"414","key":"10.1016\/j.cyto.2026.157179_bb0025","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.cyto.2026.157179_bb0030","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.cyto.2026.157179_bb0035","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12185-013-1382-0","article-title":"The biology of thrombopoietin and thrombopoietin receptor agonists","volume":"98","author":"Kuter","year":"2013","journal-title":"Int. J. Hematol."},{"issue":"1","key":"10.1016\/j.cyto.2026.157179_bb0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/imt-2017-0097","article-title":"Fostamatinib for persistent\/chronic adult immune thrombocytopenia","volume":"10","author":"Newland","year":"2018","journal-title":"Immunotherapy"},{"issue":"5","key":"10.1016\/j.cyto.2026.157179_bb0045","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40495-023-00327-x","article-title":"Pharmacokinetics and pharmacodynamics of neonatal fc receptor (FcRn)-targeting therapeutic proteins: a systemic review","volume":"9","author":"Sharma","year":"2023","journal-title":"Curr. Pharmacol. Rep."},{"key":"10.1016\/j.cyto.2026.157179_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.cyto.2026.157179_bb0250","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"issue":"1","key":"10.1016\/j.cyto.2026.157179_bb0055","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.cyto.2026.157179_bb0255","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res. Synth. Methods"},{"issue":"7109","key":"10.1016\/j.cyto.2026.157179_bb0060","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.cyto.2026.157179_bb0065","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2352-3026(23)00034-0","article-title":"Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b\/2 study","volume":"10","author":"Liu","year":"2023","journal-title":"Lancet Haematol."},{"issue":"5","key":"10.1016\/j.cyto.2026.157179_bb0070","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ajh.25444","article-title":"Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program","volume":"94","author":"Bussel","year":"2019","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.cyto.2026.157179_bb0075","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.27176","article-title":"Long-term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: an open-label extension study following a phase 3 placebo-controlled, double-blind, parallel-group study","volume":"99","author":"Kuwana","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.cyto.2026.157179_bb0080","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s12185-025-03924-2","article-title":"Long-term safety and efficacy of fostamatinib in Japanese patients with primary immune thrombocytopenia","volume":"121","author":"Kuwana","year":"2025","journal-title":"Int. J. Hematol."},{"issue":"1","key":"10.1016\/j.cyto.2026.157179_bb0085","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"issue":"8","key":"10.1016\/j.cyto.2026.157179_bb0090","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jclinepi.2006.11.003","article-title":"Effect sizes can be calculated for studies reporting ranges for outcome variables in systematic reviews","volume":"60","author":"Walter","year":"2007","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.cyto.2026.157179_bb0260","series-title":"Review Manager (RevMan) [Computer program]. Version 5.4","year":"2020"},{"issue":"7414","key":"10.1016\/j.cyto.2026.157179_bb0095","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.cyto.2026.157179_bb0100","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"6","key":"10.1016\/j.cyto.2026.157179_bb0105","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bjh.18582","article-title":"Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: a phase 3, placebo-controlled, double-blind, parallel-group study","volume":"200","author":"Kuwana","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"24","key":"10.1016\/j.cyto.2026.157179_bb0110","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1182\/blood.2024027336","article-title":"Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study","volume":"145","author":"Kuter","year":"2025","journal-title":"Blood"},{"issue":"10413","key":"10.1016\/j.cyto.2026.157179_bb0115","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/S0140-6736(23)01460-5","article-title":"Efficacy and safety of the neonatal fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Broome","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.cyto.2026.157179_bb0120","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1016\/S2352-3026(24)00139-X","article-title":"Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"11","author":"Hu","year":"2024","journal-title":"Lancet Haematol."},{"issue":"2","key":"10.1016\/j.cyto.2026.157179_bb0125","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"2","key":"10.1016\/j.cyto.2026.157179_bb0130","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/bjh.19858","article-title":"Inhibition of <scp>FcRn<\/scp> with rozanolixizumab in adults with immune thrombocytopenia: two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension","volume":"206","author":"Cooper","year":"2025","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.cyto.2026.157179_bb0135","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"28","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"19","key":"10.1016\/j.cyto.2026.157179_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127433","article-title":"Optimization of a series of potent, selective and orally bioavailable SYK inhibitors","volume":"30","author":"Grimster","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.cyto.2026.157179_bb0155","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1208\/s12248-009-9120-5","article-title":"Inhibitors of the FcRn:IgG Protein\u2013Protein Interaction","volume":"11","author":"Low","year":"2009","journal-title":"AAPS J."},{"issue":"9","key":"10.1016\/j.cyto.2026.157179_bb0160","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1007\/s10072-024-07460-5","article-title":"Efgartigimod as a novel FcRn inhibitor for autoimmune disease","volume":"45","author":"Yang","year":"2024","journal-title":"Neurol. Sci."},{"issue":"3","key":"10.1016\/j.cyto.2026.157179_bb0165","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jaci.2020.07.016","article-title":"Targeting FcRn for immunomodulation: benefits, risks, and practical considerations","volume":"146","author":"Peter","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.cyto.2026.157179_bb0190","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/JBM.S234374","article-title":"<p>platelet transfusion: and update on challenges and outcomes<\/p>","volume":"11","author":"Solves","year":"2020","journal-title":"J Blood Med."},{"key":"10.1016\/j.cyto.2026.157179_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2018.10.001","article-title":"Are thrombocytopenia and platelet transfusions associated with major bleeding in preterm neonates?","volume":"36","author":"Fustolo-Gunnink","year":"2019","journal-title":"A systematic review. Blood Rev."},{"issue":"1","key":"10.1016\/j.cyto.2026.157179_bb0200","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1185\/03007995.2011.644849","article-title":"Selective validation of the WHO bleeding scale in patients with chronic immune thrombocytopenia","volume":"28","author":"Fogarty","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"issue":"7","key":"10.1016\/j.cyto.2026.157179_bb0205","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1182\/blood-2015-02-628461","article-title":"Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP","volume":"126","author":"Frelinger","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cyto.2026.157179_bb0210","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/jha2.939","article-title":"Fostamatinib for immune thrombocytopenic purpura in adult patients: a systematic review and meta-analysis","volume":"5","author":"Kou","year":"2024","journal-title":"EJHaem"},{"issue":"9","key":"10.1016\/j.cyto.2026.157179_bb0215","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1007\/s00277-024-05824-7","article-title":"Efficacy and safety of fostamatinib in refractory immune thrombocytopenia: a meta-analysis from randomized controlled trials","volume":"103","author":"Tungjitviboonkun","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.cyto.2026.157179_bb0220","doi-asserted-by":"crossref","first-page":"5578929","DOI":"10.1155\/mi\/5578929","article-title":"Efficacy and safety of Syk and BTK inhibitors in immune thrombocytopenia: a comprehensive review of emerging evidence","volume":"2025","author":"Heidari","year":"2025","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.cyto.2026.157179_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2025.156971","article-title":"FcRn inhibitors in immune thrombocytopenia: a comprehensive review of therapeutic advances and clinical outcomes","volume":"193","author":"Nilforoushzadeh","year":"2025","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.cyto.2026.157179_bb0230","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/jox13010005","article-title":"Safety and efficacy of tyrosine kinase inhibitors in immune thrombocytopenic Purpura: a systematic review of clinical trials","volume":"13","author":"Ali","year":"2023","journal-title":"J Xenobiot."},{"issue":"1","key":"10.1016\/j.cyto.2026.157179_bb0235","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0163-7258(91)90088-4","article-title":"Biological rhythms in the absorption, distribution, metabolism and excretion of drugs","volume":"52","author":"Labrecque","year":"1991","journal-title":"Pharmacol. Ther."},{"issue":"393","key":"10.1016\/j.cyto.2026.157179_bb0240","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal2999","article-title":"The effects of treatment failure generalize across different routes of drug administration","volume":"9","author":"Zunhammer","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"1\u20132","key":"10.1016\/j.cyto.2026.157179_bb0245","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jns.2007.02.012","article-title":"Approved drugs and their problems in patient care: routes of administration and dosing","volume":"259","author":"Cook","year":"2007","journal-title":"J. Neurol. Sci."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466626000748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466626000748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:56:18Z","timestamp":1784616978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466626000748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":46,"alternative-id":["S1043466626000748"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2026.157179","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of IgG-pathway inhibitors in adult immune thrombocytopenia: A systematic review and meta-analysis with subgroup analyses of FcRn and SYK inhibitors","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2026.157179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"157179"}}